You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation . In this prospective multicentre trial , 90 patients undergoing autologous stem cell transplantation ( ASCT ) were randomised to receive ( n=43 ) or not receive ( n=47 ) amifostine 910 mg/m ( 2 ) prior to melphalan 200 mg/m ( 2 ) . Patients were monitored for regimen-related toxicity , engraftment , supportive care , response and survival . Both groups underwent ASCT at a median of 8 months from diagnosis and were matched for disease characteristics , prior therapy and pre-ASCT disease responsiveness . Amifostine infusional side-effects were frequent , occurring in 65 % of patients , but of mild severity . Amifostine use was associated with a reduction in the median grade of oral mucositis ( 1 vs 2 , P=0.01 ) and the frequency of severe ( WHO grades 3 or 4 ) mucositis ( 12 vs 33 % , P=0.02 ) , but no reduction in the requirement for parenteral nutrition or analgesic use . Conversion to complete remission post-ASCT occurred in 30 and 14 % of the amifostine and control groups , respectively ( P=0.09 ) . With a median follow-up of 35 months , there was no statistically significant difference between the median progression-free or overall survival times for the two groups . We conclude that amifostine can be safely administered prior to high-dose melphalan and significantly reduces the frequency and severity of therapy-induced oral mucositis .
{"Intervention": ["amifostine cytoprotection", "high-dose melphalan", "amifostine 910 mg/m ( 2 ) prior to melphalan 200 mg/m ( 2 )", "amifostine", "Amifostine"], "Outcome": ["median progression-free or overall survival times", "post-ASCT", "frequency of severe ( WHO grades 3 or 4 ) mucositis", "regimen-related toxicity , engraftment , supportive care , response and survival .", "frequency and severity of therapy-induced oral mucositis .", "median grade of oral mucositis", "reduction"], "Participant": ["autologous stem cell transplantation ( ASCT )", "90"]}